These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 15886218)

  • 1. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Katsaraki A; Tsianos EV
    Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Kosta P; Papadimitriou K; Tsianos EV
    J Clin Gastroenterol; 2006 Apr; 40(4):342-6. PubMed ID: 16633107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Fotopoulos A; Al Bokharhii J; Pappas C; Katsaraki A; Tsianos EV
    Am J Gastroenterol; 2005 Apr; 100(4):879-85. PubMed ID: 15784036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F; Pantea L; Sniderman K
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
    Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.
    Kalambokis G; Fotopoulos A; Economou M; Pappas K; Tsianos EV
    J Hepatol; 2007 Feb; 46(2):213-21. PubMed ID: 17156883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system.
    Lenaerts A; Codden T; Meunier JC; Henry JP; Ligny G
    Hepatology; 2006 Oct; 44(4):844-9. PubMed ID: 17006921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
    Rademaker MT; Charles CJ; Nicholls MG; Richards AM
    Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites.
    Peltekian KM; Wong F; Liu PP; Logan AG; Sherman M; Blendis LM
    Am J Gastroenterol; 1997 Mar; 92(3):394-9. PubMed ID: 9068457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biological factors influencing response to diuretics in patients with cirrhosis and ascites].
    Lenaerts A; Codden T; Henry JP; Van Cauter J; Meunier JC; Ligny G
    Gastroenterol Clin Biol; 2001 Mar; 25(3):268-72. PubMed ID: 11395674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal and humoral effects of ibopamine, a dopamine agonist, in patients with liver cirrhosis.
    Salerno F; Incerti P; Badalamenti S; Lorenzano E; Graziani G; Morganti A; Ghirardi P
    Arch Intern Med; 1990 Jan; 150(1):65-9. PubMed ID: 1967522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites.
    Yang YY; Lin HC; Lin MW; Chu CJ; Lee FY; Hou MC; Lee SD; Lee WP; Liu TT; Jap TS
    Clin Sci (Lond); 2011 Dec; 121(11):509-21. PubMed ID: 21692745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The significance of urine sodium measurement after furosemide administration in diuretics-unresponsive patients with liver cirrhosis].
    Cho HS; Park GT; Kim YH; Shim SG; Kim JB; Lee OY; Choi HS; Hahm JS; Lee MH
    Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):324-31. PubMed ID: 14695699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide in the treatment of refractory ascites of cirrhosis.
    Kalambokis G; Fotopoulos A; Economou M; Tsianos EV
    Scand J Gastroenterol; 2006 Jan; 41(1):118-21. PubMed ID: 16373285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial.
    Ottesen LH; Aagaard NK; Kiszka-Kanowitz M; Rehling M; Henriksen JH; Pedersen EB; Flyvbjerg A; Bendtsen F
    Hepatology; 2001 Sep; 34(3):471-7. PubMed ID: 11526531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.
    Gatta A; Angeli P; Caregaro L; Menon F; Sacerdoti D; Merkel C
    Hepatology; 1991 Aug; 14(2):231-6. PubMed ID: 1860680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impairment of renal function during moderate physical exercise in cirrhotic patients with ascites: relationship with the activity of neurohormonal systems.
    Saló J; Guevara M; Fernández-Esparrach G; Bataller R; Ginès A; Jimenez W; Ginès P; Rivera F; Arroyo V; Rodés J
    Hepatology; 1997 Jun; 25(6):1338-42. PubMed ID: 9185749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
    Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J
    Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites.
    Spahr L; Villeneuve JP; Tran HK; Pomier-Layrargues G
    Hepatology; 2001 Jan; 33(1):28-31. PubMed ID: 11124817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.